Oncology Clinical Trials in Baltimore, MD
As of July 2026, 283 paid clinical trials are recruiting for Oncology in Baltimore, Maryland. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
283 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
GEMINI-NSCLC: NSCLC Biomarker Study
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
About research studies in Baltimore
Baltimore has approximately 1,645 recruiting research studies across a wide range of therapeutic areas. Maryland hosts Johns Hopkins Medicine and the NIH Clinical Center in Bethesda, giving participants access to some of the most advanced early-phase research in the country.
Top Research Study Locations in Baltimore
Researchers run research studies in Baltimore, MD at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Johns Hopkins University | Cystic Fibrosis, Pancreatic Ductal Adenocarcinoma (PDAC), Prostate Cancer | 191 |
| Johns Hopkins Hospital | Barrett Esophagus, Bladder Cancer, COVID-19 | 127 |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy | 73 |
| University of Maryland | Acute Kidney Injury, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma | 62 |
| University of Maryland/Greenebaum Cancer Center | Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Acute Myeloid Leukemia | 58 |
| University of Maryland Medical Center | Heart Failure, Subarachnoid Hemorrhage, Acute Kidney Injury | 57 |
| Sinai Hospital of Baltimore | Malignant Solid Neoplasm, Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8 | 53 |
| Johns Hopkins University School of Medicine | Alcohol Use Disorder, Amputation, Traumatic, Chronic Low-back Pain | 47 |
| Johns Hopkins | Primary Immune Deficiency Disorder, Chronic Obstructive Pulmonary Disease (COPD), Atrial Fibrillation | 39 |
| Kennedy Krieger Institute | Autism Spectrum Disorder, Adrenomyeloneuropathy, Autism | 33 |
| Johns Hopkins School of Medicine | Alzheimer Disease, Bilateral Vestibular Hypofunction, Bilateral Vestibulopathy | 32 |
| Johns Hopkins Bayview Medical Center | Carcinoma, Non-Small-Cell Lung, Healthy, Sleep | 27 |
| University of Maryland School of Medicine | Acute-On-Chronic Liver Failure, Advanced or Metastatic Colorectal Cancer, Brain Injury | 24 |
| The Johns Hopkins Hospital | Achilles Tendon Repairs/Reconstructions, Ankle Fracture (Bimalleolar Equivalent, Bimalleolar, or Trimalleolar), Aortic Stenosis | 22 |
| Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD | Cognitive Impairment, Falls, Obesity | 21 |
| Greater Baltimore Medical Center | Amblyopia, Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer | 21 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Breast Cancer, Kaposi Sarcoma, Lymphoma | 19 |
| University of Maryland, Baltimore | Fatigue, Stroke, ADPKD (Autosomal Dominant Polycystic Kidney Disease) | 18 |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Prostate Cancer, Kidney Cancer, Metastatic Castration-resistant Prostate Cancer | 17 |
| Mercy Medical Center | Breast Cancer, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 17 |
| John Hopkins University | Amyotrophic Lateral Sclerosis, Advanced Solid Tumors, Allogenic Transplant Patients | 16 |
| Johns Hopkins Medicine | Achondroplasia, Acute Kidney Injury, Aging | 16 |
| Maryland Proton Treatment Center | Breast Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Biliary Tract Cancer | 16 |
| National Institute on Drug Abuse | Alcohol Use Disorder, Normal Physiology, Substance Use Disorder | 15 |
| University of Maryland Baltimore | Opioid Use Disorder, Acute Respiratory Failure, Alcohol-Related Disorders | 13 |
Active & Upcoming Studies in Baltimore (2026)
Recruiting trials in Baltimore grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (455 active studies)
- Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer · Phase 1, Phase 2 · National Cancer Institute (NCI)
- WATER IV PCa (AS Sub-study) · PROCEPT BioRobotics
Neurology & pain (125 active studies)
- Study to Examine the Effect of Silicone Mouth Tape on Snoring and Mild Sleep Apnea. · Phase 2 · Johns Hopkins University
- A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep · Phase 1, Phase 2 · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Cardiovascular (78 active studies)
- Pulmonary Hypertension (PH) Biorepository for Translational Research · National Institutes of Health Clinical Center (CC)
- Implementation of a Beauty Salon-Based Strategy for Blood Pressure Management Among Women · Johns Hopkins University
Diabetes & metabolic (56 active studies)
- Integrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood Pressure · Johns Hopkins University
- MiniMed Fit Payload Wear Pediatric Study · Medtronic MiniMed, Inc.
Mental health & behavior (51 active studies)
- Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE) · Phase 2 · VA Office of Research and Development
- Facilitation to Increase Tobacco Treatment · VA Office of Research and Development
HIV / STI (44 active studies)
- Decision Support Tool to Integrate PrEP Into Emergency Departments · Phase 1 · George Washington University
- ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing · Johns Hopkins University
Eye & vision (27 active studies)
- Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects · Phase 4 · University of Maryland, Baltimore
- Optic Nerve Head Strain in Non-glaucoma Subjects · EARLY_Phase 1 · Johns Hopkins University
Pediatric (24 active studies)
- Building Relationship, Improving Dialogue, and Growing Empathy (BRIDGE): An Intervention to Support Decision Making for Critically Ill Children · Duke University
- Measuring Brain Changes Following Cognitive Intervention in Pediatric Patients With Brain Tumors · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Vaccines (18 active studies)
- Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Common conditions studied in Baltimore
- Breast Cancer (24 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (20 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Opioid Use Disorder (19 active studies). Opioid use disorder research tests extended-release medications, novel pharmacotherapies, and harm-reduction interventions.
- Stroke (19 active studies). Stroke trials test acute reperfusion strategies, neuroprotective agents, and rehabilitation technologies to improve recovery.
- Heart Failure (17 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Acute Myeloid Leukemia (13 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
Leading research sponsors in Baltimore
- Johns Hopkins University
- University of Maryland, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- National Cancer Institute (NCI)
- AstraZeneca
Local regulations and guidelines
Clinical trials in Maryland are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Maryland research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Baltimore. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Baltimore
Hipa.ai aggregates every recruiting study in Baltimore from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Baltimore?
There are approximately 1,645 recruiting clinical trials in Baltimore, Maryland listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Baltimore pay participants?
Most recruiting trials in Baltimore compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Baltimore?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Baltimore?
The most common conditions under active study in Baltimore include Breast Cancer (24), Prostate Cancer (20), Opioid Use Disorder (19), Stroke (19), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Baltimore?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Baltimore on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Baltimore?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Baltimore?
Recruiting research sites in Baltimore include Johns Hopkins University, Johns Hopkins Hospital, Johns Hopkins University/Sidney Kimmel Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Baltimore right now?
The largest active categories in Baltimore are Cancer & tumors (455), Neurology & pain (125), Cardiovascular (78). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.